Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 7/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.40 |
| ▸ | MEN1 | O00255 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17445480 | 0.94 | KMT2A (0.44) | MAPTNPSR1MAPK1TSHRHSD17B10 | |
| SCHEMBL17451673 | 0.93 | MAPT (0.45) | MAPTNPSR1MAPK1TSHRHSD17B10 | |
| SCHEMBL17445479 | 0.93 | KMT2A (0.47) | MAPTNPSR1MAPK1TSHRHSD17B10 | |
| SCHEMBL19046673 | 0.92 | KMT2A (0.42) | MAPTNPSR1MAPK1TSHRHSD17B10 | |
| SCHEMBL19046670 | 0.92 | KMT2A (0.42) | MAPTNPSR1MAPK1TSHRHSD17B10 | |
| SCHEMBL17445372 | 0.91 | MAPT (0.39) | MAPTNPSR1MAPK1TSHRHSD17B10 | |
| SCHEMBL20311805 | 0.91 | MAPT (0.41) | MAPTNPSR1MAPK1TSHRHSD17B10 | |
| SCHEMBL20312033 | 0.91 | MAPT (0.41) | MAPTNPSR1MAPK1TSHRHSD17B10 | |
| SCHEMBL17451674 | 0.90 | KMT2A (0.45) | MAPTNPSR1MAPK1HPGDKMT2A | |
| SCHEMBL17451668 | 0.90 | KMT2A (0.45) | MAPTNPSR1MAPK1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9780314-B2 | Compound for organic electric element, organic electric element comprising the same and electronic device thereof | DUK SAN NEOLUX CO., LTD. (KR) | 2017-10-03 | — | — | US | disclosed |
| US-9780314-B2 | Compound for organic electric element, organic electric element comprising the same and electronic device thereof | DUK SAN NEOLUX CO., LTD. (KR) | 2017-10-03 | — | — | US | disclosed |
| US-20160020408-A1 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT COMPRISING THE SAME AND ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2016-01-21 | — | — | US | disclosed |
| US-20160020408-A1 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT COMPRISING THE SAME AND ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160020408-A1 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT COMPRISING THE SAME AND ELECTRONIC DEVICE THEREOF | OR51E2, NFE2L2, ORAI2 | MAPT 1456/4885NPSR1 4798/4885MAPK1 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.